according to the Hazardous Products Regulations



# **Gentamicin / Betamethasone Ointment Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.11 09/30/2023 1841324-00015 Date of first issue: 07/19/2017

#### **SECTION 1. IDENTIFICATION**

Product name : Gentamicin / Betamethasone Ointment Formulation

Other means of identification : No data available

### Manufacturer or supplier's details

Company name of supplier : Organon & Co.

Address : 30 Hudson Street, 33nd floor

Jersey City, New Jersey, U.S.A 07302

Telephone : 1-551-430-6000 Emergency telephone : 1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

#### **SECTION 2. HAZARDS IDENTIFICATION**

### GHS classification in accordance with the Hazardous Products Regulations

Reproductive toxicity : Category 1A

Specific target organ toxicity

- repeated exposure

Category 1 (Pituitary gland, Immune system, muscle, thymus

gland, Blood, Adrenal gland)

### **GHS label elements**

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H360D May damage the unborn child.

H372 Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through pro-

longed or repeated exposure.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust, fume, gas, mist, vapors or spray.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product. P280 Wear protective gloves, protective clothing, eye protection

and face protection.

according to the Hazardous Products Regulations



# Gentamicin / Betamethasone Ointment Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/04/2023 09/30/2023 1841324-00015 Date of first issue: 07/19/2017 3.11

Response:

P308 + P313 IF exposed or concerned: Get medical attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

Other hazards

None known.

### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture Mixture

## Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Petrolatum	White Vaseline	8009-03-8	94.8
Paraffin oil	No data availa- ble	8012-95-1	5
Gentamicin	No data availa- ble	1403-66-3	0.1
Betamethasone	No data availa- ble	378-44-9	0.064

### **SECTION 4. FIRST AID MEASURES**

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse. Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

In case of eye contact

delayed

May damage the unborn child. Causes damage to organs through prolonged or repeated

exposure.

according to the Hazardous Products Regulations



# **Gentamicin / Betamethasone Ointment Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.11 09/30/2023 1841324-00015 Date of first issue: 07/19/2017

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

#### **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- :

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protec- :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

### **SECTION 7. HANDLING AND STORAGE**

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

according to the Hazardous Products Regulations



# **Gentamicin / Betamethasone Ointment Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.11 09/30/2023 1841324-00015 Date of first issue: 07/19/2017

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust, fume, gas, mist, vapors or spray.

Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety

practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Petrolatum	8009-03-8	TWA (Mist)	5 mg/m³	CA AB OEL
		STEL (Mist)	10 mg/m <sup>3</sup>	CA AB OEL
		TWA (Mist)	1 mg/m³	CA BC OEL
		TWAEV (Mist - Inhalable dust)	5 mg/m³	CA QC OEL
		TWA (Inhalable particulate matter)	5 mg/m³	ACGIH
Paraffin oil	8012-95-1	TWA (Mist)	5 mg/m <sup>3</sup>	CA AB OEL
		STEL (Mist)	10 mg/m <sup>3</sup>	CA AB OEL
		TWA (Mist)	1 mg/m³	CA BC OEL
		TWAEV (Mist - Inhalable dust)	5 mg/m³	CA QC OEL
		TWA (Inhalable particulate	5 mg/m³	ACGIH

according to the Hazardous Products Regulations



# Gentamicin / Betamethasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.11 09/30/2023 1841324-00015 Date of first issue: 07/19/2017

		matter)					
Gentamicin	1403-66-3	TWA	0.1 mg/m3 (OEB	Internal			
			2)				
	Further inforr	Further information: OTO					
Betamethasone	378-44-9	TWA	1 μg/m3 (OEB 4)	Internal			
	Further inforr	Further information: Skin					
		Wipe limit	10 μg/100 cm <sup>2</sup>	Internal			

**Engineering measures** Containment technologies suitable for controlling compounds

are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from

stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

Personal protective equipment

Respiratory protection If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection. Combined particulates and organic vapor type

Filter type

Hand protection

Material Chemical-resistant gloves

Remarks Consider double gloving.

Eye protection Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection Work uniform or laboratory coat.

> Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

according to the Hazardous Products Regulations



# **Gentamicin / Betamethasone Ointment Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.11 09/30/2023 1841324-00015 Date of first issue: 07/19/2017

#### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : ointment

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not classified as a flammability hazard

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

according to the Hazardous Products Regulations



# Gentamicin / Betamethasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 1841324-00015 Date of first issue: 07/19/2017 3.11 09/30/2023

Oxidizing properties The substance or mixture is not classified as oxidizing.

Molecular weight No data available

Particle size No data available

### **SECTION 10. STABILITY AND REACTIVITY**

Reactivity Not classified as a reactivity hazard. Chemical stability Stable under normal conditions. Can react with strong oxidizing agents.

Possibility of hazardous reac-

tions

Conditions to avoid None known. Incompatible materials Oxidizing agents

Hazardous decomposition No hazardous decomposition products are known.

products

#### **SECTION 11. TOXICOLOGICAL INFORMATION**

### Information on likely routes of exposure

Skin contact Ingestion Eye contact

### **Acute toxicity**

Not classified based on available information.

### Components:

### Petrolatum:

LD50 (Rat): > 5,000 mg/kg Acute oral toxicity

Method: OECD Test Guideline 401

Remarks: Based on data from similar materials

Acute dermal toxicity LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Remarks: Based on data from similar materials

Paraffin oil:

: LD50 (Rat): > 5,000 mg/kg Acute oral toxicity

LD50 (Rabbit): > 2,000 mg/kg Acute dermal toxicity

Assessment: The substance or mixture has no acute dermal

toxicity

according to the Hazardous Products Regulations



# **Gentamicin / Betamethasone Ointment Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.11 09/30/2023 1841324-00015 Date of first issue: 07/19/2017

Gentamicin:

Acute oral toxicity : LD50 (Rat): 8,000 - 10,000 mg/kg

LD50 (Mouse): 10,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0.2 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Remarks: No mortality observed at this dose.

Acute toxicity (other routes of :

administration)

LD50 (Rat): 67 - 96 mg/kg

Application Route: Intravenous

LD50 (Rat): 371 - 384 mg/kg Application Route: Intramuscular

LDLo (Monkey): 30 mg/kg Application Route: Intravenous

Betamethasone:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

LD50 (Mouse): > 4,500 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0.4 mg/l

Exposure time: 4 h

## Skin corrosion/irritation

Not classified based on available information.

### **Components:**

Petrolatum:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Remarks : Based on data from similar materials

Paraffin oil:

Species : Rabbit

Result : No skin irritation

Gentamicin:

Species : Rabbit

Result : Mild skin irritation

Betamethasone:

Species : Rabbit

Result : Mild skin irritation

according to the Hazardous Products Regulations



# Gentamicin / Betamethasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.11 09/30/2023 1841324-00015 Date of first issue: 07/19/2017

### Serious eye damage/eye irritation

Not classified based on available information.

## Components:

Petrolatum:

Species : Rabbit

Result : No eye irritation

Method : OECD Test Guideline 405

Remarks : Based on data from similar materials

Paraffin oil:

Species : Rabbit

Result : No eye irritation

Gentamicin:

Species : Rabbit

Result : Mild eye irritation

Betamethasone:

Species : Rabbit

Result : No eye irritation

### Respiratory or skin sensitization

#### Skin sensitization

Not classified based on available information.

### Respiratory sensitization

Not classified based on available information.

### **Components:**

### Petrolatum:

Test Type : Buehler Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Remarks : Based on data from similar materials

Gentamicin:

Remarks : No data available

Betamethasone:

Routes of exposure : Dermal Species : Guinea pig Result : Weak sensitizer

according to the Hazardous Products Regulations



# **Gentamicin / Betamethasone Ointment Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.11 09/30/2023 1841324-00015 Date of first issue: 07/19/2017

Germ cell mutagenicity

Not classified based on available information.

**Components:** 

Petrolatum:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro

Result: negative

Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection Method: OECD Test Guideline 474

Result: negative

Remarks: Based on data from similar materials

Gentamicin:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: equivocal

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intravenous injection

Result: negative

Betamethasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse Application Route: Oral Result: equivocal

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

according to the Hazardous Products Regulations



# **Gentamicin / Betamethasone Ointment Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.11 09/30/2023 1841324-00015 Date of first issue: 07/19/2017

### Carcinogenicity

Not classified based on available information.

### **Components:**

Petrolatum:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Gentamicin:

Carcinogenicity - Assess-

ment

No data available

Reproductive toxicity

May damage the unborn child.

**Components:** 

Petrolatum:

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening

test

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Skin contact

Result: negative

Remarks: Based on data from similar materials

Gentamicin:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Fertility: NOAEL: 20 mg/kg body weight

Result: No significant adverse effects were reported

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rabbit

Developmental Toxicity: NOAEL: 3.6 mg/kg body weight

Result: No embryo-fetal toxicity.

Test Type: Embryo-fetal development

Species: Rat

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 75 mg/kg body weight

Result: Embryo-fetal toxicity.

Test Type: Embryo-fetal development

according to the Hazardous Products Regulations



# **Gentamicin / Betamethasone Ointment Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.11 09/30/2023 1841324-00015 Date of first issue: 07/19/2017

Species: Mouse

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 10 mg/kg body weight Result: Fetal mortality., No malformations were observed.

Test Type: Embryo-fetal development

Species: Rat

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 50 mg/kg body weight Result: Fetal mortality., No malformations were observed.

Reproductive toxicity - As-

sessment

Positive evidence of adverse effects on development from

human epidemiological studies.

Betamethasone:

Effects on fetal development : Species: Rabbit

Application Route: Intramuscular

Developmental Toxicity: LOAEL: 0.05 mg/kg body weight Result: Fetotoxicity., Malformations were observed.

Species: Rat

Application Route: Subcutaneous

Developmental Toxicity: LOAEL: 0.42 mg/kg body weight

Result: Malformations were observed.

Species: Mouse

Application Route: Intramuscular

Developmental Toxicity: LOAEL: 1 mg/kg body weight

Result: Malformations were observed.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments.

### STOT-single exposure

Not classified based on available information.

## STOT-repeated exposure

Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.

### **Components:**

Gentamicin:

Target Organs : Kidney, inner ear

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Betamethasone:

Target Organs : Pituitary gland, Immune system, muscle, thymus gland, Blood,

Adrenal gland

Assessment : Causes damage to organs through prolonged or repeated

according to the Hazardous Products Regulations



# **Gentamicin / Betamethasone Ointment Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.11 09/30/2023 1841324-00015 Date of first issue: 07/19/2017

exposure.

### Repeated dose toxicity

### **Components:**

# Petrolatum:

Species : Rat

NOAEL : 5,000 mg/kg
Application Route : Ingestion
Exposure time : 2 y

### Paraffin oil:

Species : Rat, female
LOAEL : 161 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

#### Gentamicin:

Species : Dog
LOAEL : 3 mg/kg
Application Route : Intramuscular
Exposure time : 12 Months
Target Organs : Kidney

Symptoms : Vomiting, Salivation

Species : Monkey
LOAEL : 50 mg/kg
Application Route : Subcutaneous
Exposure time : 3 Weeks

Target Organs : Kidney, inner ear

Species : Monkey
LOAEL : 6 mg/kg
Application Route : Intramuscular
Exposure time : 3 Weeks

Target Organs : Blood, Kidney, inner ear, Liver

Species : Rat

NOAEL : 5 mg/kg

LOAEL : 10 mg/kg

Application Route : Intramuscular

Exposure time : 52 Weeks

Target Organs : Kidney, Blood

Species : Rat

NOAEL : 12.5 mg/kg
LOAEL : 50 mg/kg
Application Route : Intramuscular
Exposure time : 13 Weeks
Target Organs : Kidney

according to the Hazardous Products Regulations



# **Gentamicin / Betamethasone Ointment Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.11 09/30/2023 1841324-00015 Date of first issue: 07/19/2017

Betamethasone:

Species : Rabbit
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 10 - 30 d

Target Organs : Pituitary gland, Immune system, muscle

Species : Rat
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

Species : Mouse
LOAEL : 0.1 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

Species : Dog

LOAEL : 0.05 mg/kg Application Route : Oral

Exposure time : 28 d

Target Organs : Blood, thymus gland, Adrenal gland

### **Aspiration toxicity**

Not classified based on available information.

#### Components:

#### Paraffin oil:

The substance or mixture is known to cause human aspiration toxicity hazards or has to be regarded as if it causes a human aspiration toxicity hazard.

### **Experience with human exposure**

### **Components:**

### Gentamicin:

Ingestion : Target Organs: Kidney

Target Organs: inner ear

Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal

deafness

Betamethasone:

Inhalation : Target Organs: Adrenal gland

Skin contact : Symptoms: Redness, pruritis, Irritation

according to the Hazardous Products Regulations



# **Gentamicin / Betamethasone Ointment Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.11 09/30/2023 1841324-00015 Date of first issue: 07/19/2017

#### **SECTION 12. ECOLOGICAL INFORMATION**

### **Ecotoxicity**

### **Components:**

Petrolatum:

Toxicity to fish : LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 203

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 10,000 mg/l

Exposure time: 48 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

NOEL (Pseudokirchneriella subcapitata (green algae)): >=

100 mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 10 mg/l

Exposure time: 21 d

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Paraffin oil:

Toxicity to fish : LL50 (Scophthalmus maximus (turbot)): > 100 mg/l

Exposure time: 96 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EL50 (Acartia tonsa (Calanoid copepod)): > 100 mg/l

Exposure time: 48 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

: EL50 (Skeletonema costatum (marine diatom)): > 100 mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

NOELR (Skeletonema costatum (marine diatom)): > 1 mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

according to the Hazardous Products Regulations



# Gentamicin / Betamethasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.11 09/30/2023 1841324-00015 Date of first issue: 07/19/2017

Gentamicin:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 86 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

LC50 (Americamysis): 30 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 10 μg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 1.5

μg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

EC50 (Anabaena flos-aquae (cyanobacterium)): 4.7 μg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 1.6 µg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50: 288.7 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Betamethasone:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Americamysis): > 50 mg/l

Exposure time: 96 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 34

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 34

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.052 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

NOEC (Oryzias latipes (Japanese medaka)): 0.07 µg/l

according to the Hazardous Products Regulations



# Gentamicin / Betamethasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 09/30/2023 1841324-00015 Date of first issue: 07/19/2017 3.11

Exposure time: 219 d

Method: OECD Test Guideline 229

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 8 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

### Persistence and degradability

### **Components:**

Petrolatum:

Biodegradability Result: Not readily biodegradable.

Biodegradation: 31 % Exposure time: 28 d

Method: OECD Test Guideline 301F

Remarks: Based on data from similar materials

Gentamicin:

Biodegradability Result: rapidly degradable

> Biodegradation: 100 % Exposure time: 28 d

Method: OECD Test Guideline 314

### **Bioaccumulative potential**

### **Components:**

Paraffin oil:

Partition coefficient: n-:  $\log Pow: > 4$ 

Remarks: Calculation octanol/water

Gentamicin:

Partition coefficient: n-

 $\log Pow: < -2$ 

octanol/water

Partition coefficient: n-

log Pow: 2.11

octanol/water

Mobility in soil No data available

Betamethasone:

Other adverse effects

No data available

### **SECTION 13. DISPOSAL CONSIDERATIONS**

**Disposal methods** 

Waste from residues Do not dispose of waste into sewer.

according to the Hazardous Products Regulations



# **Gentamicin / Betamethasone Ointment Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.11 09/30/2023 1841324-00015 Date of first issue: 07/19/2017

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

#### **SECTION 14. TRANSPORT INFORMATION**

### **International Regulations**

**UNRTDG** 

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone, Gentamicin)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

**IATA-DGR** 

UN/ID No. : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.

(Betamethasone, Gentamicin)

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo

aircraft)

956

Packing instruction (passen-

ger aircraft)

956

Environmentally hazardous : yes

**IMDG-Code** 

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Betamethasone, Gentamicin)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### **Domestic regulation**

**TDG** 

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Betamethasone, Gentamicin)

Class : 9

according to the Hazardous Products Regulations



# **Gentamicin / Betamethasone Ointment Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.11 09/30/2023 1841324-00015 Date of first issue: 07/19/2017

Packing group : III Labels : 9 ERG Code : 171

Marine pollutant : yes(Betamethasone, Gentamicin)

#### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

#### **SECTION 15. REGULATORY INFORMATION**

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

### **SECTION 16. OTHER INFORMATION**

### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CA AB OEL : Canada. Alberta, Occupational Health and Safety Code (table

2: OEL)

CA BC OEL : Canada. British Columbia OEL

CA QC OEL : Québec. Regulation respecting occupational health and safe-

ty, Schedule 1, Part 1: Permissible exposure values for air-

borne contaminants

ACGIH / TWA : 8-hour, time-weighted average
CA AB OEL / TWA : 8-hour Occupational exposure limit
CA AB OEL / STEL : 15-minute occupational exposure limit

CA BC OEL / TWA : 8-hour time weighted average

CA QC OEL / TWAEV : Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Or-

according to the Hazardous Products Regulations



# **Gentamicin / Betamethasone Ointment Formulation**

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.11 09/30/2023 1841324-00015 Date of first issue: 07/19/2017

ganisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate: NOM - Official Mexican Norm: NTP - National Toxicology Program: NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to

compile the Material Safety

**Data Sheet** 

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 09/30/2023 Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8